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Received April 15, 2016; accepted May 12, 2016AbstractBackground: Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome secondary to acute or chronic liver failure. However, its
pathophysiology remains obscure. Recently, we found that the inhibition of cyclooxygenase by indomethacin aggravated HE in rats with
thioacetamide-induced acute hepatic failure, suggesting a pivotal role of cyclooxygenase in HE. This study was aimed at surveying the roles of
cyclooxygenase isoforms responsible for prostaglandins synthesis, cyclooxygenase-1 (COX1) and COX2, in cirrhotic rats with HE.
Methods: Liver cirrhosis was induced (using formalin) in male SpragueeDawley rats with bile duct ligation (FBDL). Sham-operated rats served
as the surgical controls. The severity of HE was assessed by motor activity counts. Plasma 6-keto-prostaglandin-F1a [6-keto-PGF1a; a relatively
stable metabolite of prostacyclin (PGI2)], alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALK-P), and total
bilirubin were measured. Hepatic mRNA expressions of COX1 and COX2 were tested.
Results: The FBDL group showed lower motor activity counts than the sham group in total (1472 ± 156 vs. 2174 ± 262 counts/30 min,
p ¼ 0.034), ambulatory (824 ± 99 vs. 1443 ± 206 counts/30 min, p ¼ 0.014), and vertical movement (431 ± 69 vs. 849 ± 145 counts/30 min,
p ¼ 0.018). The mRNA expression of hepatic COX2 was significantly higher in the FBDL group. Plasma ALK-P and bilirubin levels were
negatively correlated with total movements, respectively (both p < 0.05). In addition, hepatic COX2 mRNA expression was positively correlated
with AST, ALK-P, total bilirubin, and 6-keto-PGF1a (all p < 0.05), but not correlated with total movements.
Conclusion: Hepatic COX2 expression and PGI2 production are enhanced in cirrhotic rats, but the correlation with HE is not remarkable.
Cyclooxygenase and PGI2 may not play important roles in HE in the setting of chronic liver failure.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hepatic encephalopathy (HE) is a neuropsychiatric
derangement associated with acute or chronic hepatic
decompensation with or without portal-systemic shunts.1,2 The
disorder consists of a diversity of symptoms, varying from
trivial mental instability or memory impairment to confusion,
coma, and death. The initiation and maintenance of HE have
been ascribed to several substances, such as ammonia,sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
584 H.-L. Ho et al. / Journal of the Chinese Medical Association 79 (2016) 583e588gamma-aminobutyric acid, benzodiazepines, aromatic amino
acids, false neurotransmitters, endotoxin, and tumor necrosis
factor-a.1e3 However, the true nature mechanism remains not
totally clarified.
Prostacyclin (PGI2), a vasodilatory prostaglandin, has been
postulated to play a role in the pathogenesis of hepatic failure
with encephalopathy. PGI2 participates in the mechanism of
hyperdynamic circulation in portal hypertensive status. For
instance, increased levels of 6-keto-prostaglandin-F1a (6-keto-
PGF1a), a stable metabolite of PGI2, have been noted in ani-
mals with portal hypertension and patients with liver
cirrhosis.4,5 The vasodilatory nature of PGI2 may contribute to
HE6: cerebral vasculature dilatation increases capillary surface
and subsequently facilitates the diffusion of noxious gut-
derived compounds, such as ammonia.7 It has also been
shown that PGI2 alters the permeability of the bloodebrain
barrier.8 Therefore, it is reasonable that PGI2 may participate,
at least partly, in the pathophysiology of HE.
The role of PGI2 during hepatic injury seems to be quite
controversial. Although raised blood prostaglandin levels have
been noted in massive hepatic necrosis,9 prostaglandins have
been shown to ameliorate hepatic insult in terms of prolonged
survival and histological improvements.10 Our previous study
showed a detrimental effect of indomethacin administration on
HE in rats with thioacetamide (TAA)-induced fulminant he-
patic failure, which is believed to be derived from nonselective
prostaglandin synthesis inhibition.11 Because indomethacin
exerts a universal blockade of two prostaglandin synthesis
isoenzymes, cyclooxygenase-1 (COX1) and cyclooxygenase-2
(COX2), the roles of COX isoforms in HE, indeed, require
further clarification.
As chronic liver parenchymal disease is amore prevalent form
ofhepatic failure and encephalopathy in clinical practice,weused
bile duct-ligated cirrhotic rats to quantitatively survey the degree
of HE with motor activities.12e14 The plasma levels of 6-keto-
PGF1a and liver biochemistry parameters were also measured,
and the hepatic COX isoform expressions were evaluated.
Furthermore, the correlations between them were assessed.
2. Methods2.1. Animal modelMale SpragueeDawley rats weighing 240e270 g were
used for this study. The rats were caged at 24C, with a 12-
hour lightedark cycle and free access to food and water
until the time of the experiments. Rats with secondary biliary
cirrhosis were induced by common bile duct ligation (BDL).15
Under ketamine anesthesia (100 mg/kg, intramuscularly), the
common bile duct was exposed through a midline abdominal
incision, catheterized by a PE-10 catheter and doubly ligated
with 3e0 silk. The first ligature was made below the junction
of the hepatic ducts and the second above the entrance of the
pancreatic duct. Ten percent formalin (~10 mL/100 g) was
slowly injected into the biliary tree to prevent the subsequent
dilatation of the ligated residual bile duct. Thus, this animal
model is abbreviated as FBDL. The PE-10 catheter was thenremoved and the ligatures were tightened, followed by
sectioning of the common bile duct between the ligatures. The
incision was then closed, and the animal was allowed to
recover. A high yield of secondary biliary cirrhosis was noted
at least 4 weeks after the ligation.15e17 To avoid coagulation
defects, FBDL rats received weekly vitamin K injection
(50 mg/kg, intramuscularly).18 The studies were performed in
overnight-fasted rats, 6 weeks after the operation. Two series
of studies were performed. In the first series, after measure-
ments of the motor activities, heparinized blood samples were
obtained from the inferior vena cava for alanine transaminase
(ALT), aspartate transaminase (AST), alkaline phosphatase
(ALK-P), total bilirubin, and PGF1a measurements (n ¼ 10 for
each group). In the second series, livers were dissected and
removed for RNA extraction and reverse transcription-
polymerase chain reaction (RT-PCR; n ¼ 9 for each group).
The animal experiments were conducted according to Guide
for the Care and Use of Laboratory Animals, prepared by the
National Academy of Sciences and published by the National
Institutes of Health (NIH publication 86-23 revised 1985).2.2. Measurement of motor activitiesThe severity of HE was quantified with motor activities.
Motor activities in an open field were determined using the
Opto-Varimex animal activity meter (Columbus Instruments,
Inc., Columbus, OH, USA).12,18 The Opto-Varimex activity
sensors utilize high-intensity, modulated infrared light beams
to detect animal motion. Animals were housed in transparent
cages (17  17  8 inches), through which 30 infrared beams
passed in the horizontal plane, 15 on each axis. This device
differentiated nonambulatory movements (scratching, gnaw-
ing) from ambulation on the basis of consecutive interruption
of the infrared monitoring beams. An additional row of
infrared beams in the horizontal plane (15 on each axis) about
10 cm above the floor was used to count vertical movements.
During the activity measurements, animals had no access to
food or chow. All studies were performed under strictly
standardized conditions in a dark room for 30 minutes.
Counted numbers of total movements, ambulatory movements,
and vertical movements were separately recorded to reflect the
motor activities of the rats.2.3. Determination of plasma 6-keto-PGF1a levelsHeparinized blood was centrifuged at 1789g for 10 mi-
nutes, then the plasma was separated, added with indometh-
acin (10 mg/ml), and stored under 80C. At the time of
measurement, samples were thawed, and 6-keto-PGF1a was
determined with a commercially available enzyme immuno-
assay according to the protocol supplied by the manufacturer
(R&D Systems, Minneapolis, MN, USA).2.4. RNA extraction and RT-PCRTotal RNA was extracted from the vessel with an RNeasy
Mini Kit according to the manufacturer's instructions (Qiagen
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gen) was used with the following components: 10 mL RT-PCR
buffer containing TriseHCl, KCl, (NH4)2SO4, and 2.5mM
MgCl2; 2 mL deoxynucleotide mixture containing 400mM
dATP, dCTP, dGTP, and dTTP, respectively; 2 mL enzyme
mixture containing Omniscript reverse transcriptase, Sensi-
script reverse transcriptase, and HotStar Taq DNA polymerase;
1 mL RNase inhibitor (40 U); 3 mL of each random primer
(10 pmol/mL), and 1 mg substrate RNA. RNase-free water was
added in each reaction to the final volume of 50 mL. The se-
quences of primers for COX1 were 50-
TGCATGTGGCTGTGGATGTCATCAA-30 (sense) and 50-
CACTAAGACAGACCCGTCATCTCCA-30 (antisense),
respectively. Those for COX2 were 50-ACACTCTAT-
CACTGGCATCC- 30 (sense) and 50-GAAGGGA-
CACCCTTTCACAT-30 (antisense), respectively. A
constitutively expressed gene, b-actin, was analyzed as inter-
nal control, and the primers for b-actin were 50-TTGTAAC-
CAACTGGGACGATATGG-30 (sense) and 50-
GATCTTGATCTTCATGGTGCTAGG-30 (antisense), respec-
tively. The primers for COX1, COX2, and b-actin were
designed to allow amplification of 450, 584, and 764 base-pair
(bp) fragments, respectively.20,21 A negative control was
included in each set of experiments. The tubes were placed in
a thermocycler (Biometra T Gradient thermocycler; Biometra
GmbH, G€ottingen, Germany) at 50C for 30 minutes for RT,
95C for 15 minutes for initial denaturation, followed by 35
cycles of the following sequential steps: 30 seconds at 94C
(denaturation), 45 seconds at 56C for COX-1, 57.2C for
COX-2, 59.6C for b-actin (annealing), respectively, and
45 seconds at 72C (extension). The final extension was per-
formed at 72C for 10 minutes. Then, 10 mL of the PCR-
amplified mixture was subjected to electrophoresis on a 2%
agarose gel, and DNA was visualized by ethidium bromide
staining. Location of the predicted PCR products (base pairs)
was confirmed with a 100-bp ladder (Gibco BRL, Gaithers-
burg, MD, USA) as standard size marker. The gel was then
photographed, and the PCR products were quantitated by a
digitalized software (Kodak Digital Science ID Image Anal-
ysis Software; Eastman Kodak Company, Rochester, NY,
USA). The intensities of COX1 and COX2 signals were
standardized against that of b-actin from the same RNA
sample and expressed as COX1/b-actin and COX2/b-actin
ratio for comparison.2.5. Data analysisAll results are expressed as mean ± standard error of the
mean. Statistical analyses were performed using Student t test.
Results were considered statistically significant at p < 0.05.
3. Results3.1. Motor activitiesFig. 1 shows the motor activities of the FBDL and control
(sham) groups. The FBDL group showed lower motor activitycounts than those of the control group in total (FBDL vs.
control: 1472 ± 156 vs. 2174 ± 262 counts/30 min;
p ¼ 0.034), ambulatory (824 ± 99 vs. 1443 ± 206 counts/
30 min, p ¼ 0.014), and vertical movements (431 ± 69 vs.
849 ± 145 counts/30 min, p ¼ 0.018).3.2. Plasma ALT, AST, ALK-P, bilirubin, and 6-keto-
PGF1a levelsTable 1 shows the plasma concentrations of ALT, AST,
ALK-P, bilirubin, and 6-keto-PGF1a of the two experimental
groups. They were significantly higher in the FBDL group (all
p < 0.05).3.3. Cyclooxygenases expressionFig. 2 shows the hepatic COX1 and COX2 mRNA ex-
pressions. Hepatic COX2 expression was significantly higher
in the FBDL group (COX2/b-actin: 0.41 ± 0.04 vs.
0.13 ± 0.03, p < 0.001). However, the hepatic COX1 mRNA
expression (COX1/b-actin: 1.13 ± 0.11 vs. 0.90 ± 0.08,
p ¼ 0.117) was not significantly different between the two
groups.3.4. Correlations between severity of hepatic injury, HE,
and hepatic COX expressionFigs. 3 and 4 depict the correlations among the aforemen-
tioned parameters. Plasma ALK-P and bilirubin levels were
negatively correlated with total movements ( p ¼ 0.035,
g ¼ 0.474; p ¼ 0.009, g ¼ 0.569, respectively). In addi-
tion, hepatic COX2 mRNA expression was positively corre-
lated with AST, ALK-P, bilirubin, and 6-keto-PGF1a
( p ¼ 0.004, g ¼ 0.608; p < 0.001, g ¼ 0.745; p ¼ 0.001,
g ¼ 0.700; and p < 0.001, g ¼ 0.722, respectively). However,
there was no significant relationship between hepatic COX2
mRNA expression or 6-keto-PGF1a level and total movements.
4. Discussion
Different from animal models with acute hepatic damage,
the BDL model is an applicable model of chronic liver disease
with moderate to severe degree of hepatic injury and modest or
moderate degree of shunting.17,22,23 In our previous study, we
demonstrated that BDL rats steadily developed HE.24
Compatible with that previous finding, we also found mark-
edly decreased motor activities in the current FBDL group.
In the present study, the FBDL rats showed significantly
elevated plasma levels of ALT, AST, ALK-P, and bilirubin,
compatible with cholestatic liver injury. The 6-keto-PGF1a
level was also elevated, consistent with previous studies: The
vasodilatory prostanoids, especially PGI2, have been impli-
cated as mediators of the systemic and splanchnic hyperemia
characteristic of portal hypertension.5,25 The increased portal
venous PGI2 levels may maintain the portal hypertensive state
in cirrhotic patients.26 In addition, plasma and urinary levels of
6-keto-PGF1a were higher in rats with portal vein stenosis and
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Fig. 1. Individual and mean values of total, ambulatory and vertical movements (counts/30 min) of control (sham) and FBDL rats. FDBL ¼ formalin-injected rats
with bile duct ligation.
Table 1
Parameters of hepatic injury and PGF1-a in FBDL and control groups.
ALT (U/L) AST (U/L) ALK-P (U/L) Bilirubin
(mg/dL)
PGF1-a (pg/mL)
FBDL 93 ± 17 421 ± 46 358 ± 13 7.4 ± 0.7 3626 ± 601
Control 29 ± 1 77 ± 6 158 ± 7 0.1 ± 0.0 1362 ± 167
p 0.001 <0.001 <0.001 <0.001 0.002
ALT ¼ alanine transaminase; AST ¼ aspartate transaminase; ALK-
P ¼ alkaline phosphatase; FBDL ¼ formalin-injected rats with bile duct
ligation; PGF1-a ¼ prostaglandin F1a.
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in cirrhotic patients was also increased.4
PGI2 has been postulated to take part in the pathogenesis of
HE.6 PGI2 altered the permeability of the bloodebrain bar-
rier.8 In addition, cerebral vasculature dilatation may increase
capillary surface and subsequently facilitate the diffusion ofFig. 2. Representative diagram of agarose gel electrophoresis of COX1 and COX2
ladder; COX1: 450 bp; COX2: 584 bp). Semiquantitative RT-PCR analy
COX1 ¼ cyclooxygenase-1; COX-2 ¼ cyclooxygenase-2; FDBL ¼ formalin-inje
chain reaction.noxious gut-derived compounds, such as ammonia.7 The
absence of cerebral blood flow autoregulation in TAA-induced
acute liver failure appears to arise from cerebral arteriolar
dilatation28e30 and brain edema has been found in cirrhotic
patients with HE.31 In addition, indomethacin, an inhibitor of
cyclooxygenase, has been considered a cerebral vasocon-
strictor.32 The administration of indomethacin decreased ce-
rebral blood flow, brain water, and intracranial pressure in rats
that underwent portocaval anastomosis.33 A retrospective
study also revealed a strong relationship among cerebral blood
flow, brain swelling, outcome, and depth of coma.34 Therefore,
it is reasonable that PGI2 may participate in the pathophysi-
ology of hepatic coma, and pharmacological manipulation of
the cerebral circulation might prevent the development of
brain edema in hepatic failure. However, according to our
recent study,11 indomethacin, a nonselective COX inhibitor,
exerted detrimental effects in terms of mortality and severitycDNA: (A) liver of control rats (A) and (B) FBDL rats (marker: 100-bp DNA
sis: (C) COX1 expression. (D) COX2 expression. bp ¼ base pairs.
cted rats with bile duct ligation; RT-PCR ¼ reverse transcription-polymerase
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Fig. 3. Correlations between severity of hepatic encephalopathy (total movements) and plasma levels of alkaline phosphatase (ALK-P) and bilirubin.
Fig. 4. Correlations between hepatic COX2 mRNA expression and plasma levels of AST, ALK-P, bilirubin, and 6-keto-PGF1a. ALK-P ¼ alkaline phosphatase;
AST ¼ aspartate transaminase; COX-2 ¼ cyclooxygenase-2; 6-keto-PGF1a ¼ 6-keto-prostaglandin-F1a.
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ure. By contrast, no detrimental or therapeutic effect was
identified in BDL rats receiving indomethacin.35 These find-
ings suggest different roles of COX in acute and chronic liver
failure-induced HE.
Interestingly, a previous study identified that a COX1 in-
hibitor, SC-560, significantly improved HE in rats with TAA-
induced fulminant hepatic failure,36 implying that COX1 plays
a significant role in HE related to acute liver failure. In the
current study, although hepatic COX2 expression was upre-
gulated in FBDL rats with HE, there was no significant cor-
relation between hepatic COX2 expression and motor
activities. Rather, the motor activities correlated with ALK-P
and bilirubin, two parameters of cholestatic liver damage.
Furthermore, hepatic COX1 expression was not significantlydifferent between FBDL and sham rats. The results indicated
that first, compatible with our previous finding,37 HE in
FBDL-cirrhotic rats is correlated with the severity of chole-
static liver injury rather than portosystemic shunting; second,
the pathophysiological mechanism of HE in cirrhosis is
multifactorial and not limited to prostaglandins.
Prostaglandins have been shown to reverse acute experi-
mental hepatic damage.10 Indomethacin administration
following liver damage induced by carbon tetrachloride also
increased liver cell death in rats.38 The previous investigations
have indicated that PGI2 may exert a protective effect on liver
damage attributed to its lysosomal membrane stabilization
effect.39,40 Another study addressed that although PGI2 did not
induce vasodilatory effects on the hepatic circulation, it
exerted a beneficial action by inducing redistribution of flow to
588 H.-L. Ho et al. / Journal of the Chinese Medical Association 79 (2016) 583e588certain areas of the liver or by decreasing hepatic shunt flow.40
We found in the present study that hepatic COX2 mRNA
expression was enhanced in BDL rats. Interestingly, the he-
patic COX2 expression correlated with AST, ALK-P, and
bilirubin levels. Whether it is activated following liver injury
to modulate the hepatic circulation or the COX2 over-
expression actually damages liver function remains to be
clarified, and further studies are required.
In conclusion, although hepatic COX2 mRNA over-
expression and an increased plasma level of PGF1a were found
in FBDL rats with HE, they were not significantly correlated
with the severity of HE, suggesting a multifactorial and
complicated nature of HE in cirrhosis.
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